Stay updated on SNDX-6352 & Durvalumab in Solid Tumors Clinical Trial
Sign up to get notified when there's something new on the SNDX-6352 & Durvalumab in Solid Tumors Clinical Trial page.

Latest updates to the SNDX-6352 & Durvalumab in Solid Tumors Clinical Trial page
- Check4 days agoChange DetectedThe changes are limited to layout/formatting with no new eligibility criteria, endpoints, locations, or study status updated. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.4%

- Check12 days agoNo Change Detected
- Check33 days agoChange DetectedVersion bumped to v3.2.0 with an added government-operating-status notice; the previous v3.1.0 deletion indicates the page now reflects the updated version.SummaryDifference1%

- Check40 days agoChange Detected- Updated version from v3.0.2 to v3.1.0. - No other content changes detected.SummaryDifference0.0%

- Check55 days agoChange DetectedPage revision updated from v3.0.1 to v3.0.2, and the 'Back to Top' element was removed. No substantive changes to core content, pricing, stock, or time-related information.SummaryDifference0.1%

- Check62 days agoChange DetectedThe web page has been updated from version 3.0.0 to 3.0.1, indicating a revision in the content. There are no significant changes to core content or other important elements.SummaryDifference0.1%

- Check69 days agoChange DetectedThe web page has updated its facility name and location details, while also adding specific drug names such as Axatilimab and Durvalumab. Additionally, the revision number has been updated to v3.0.0.SummaryDifference0.8%

Stay in the know with updates to SNDX-6352 & Durvalumab in Solid Tumors Clinical Trial
Enter your email address, and we'll notify you when there's something new on the SNDX-6352 & Durvalumab in Solid Tumors Clinical Trial page.